US Patent Issued to CARBIOGENE THERAPEUTICS on Feb. 17 for "Chimeric antigen receptor t lymphocyte for treating tumors, preparation method therefor, and use thereof" (Chinese Inventors)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,552,852, issued on Feb. 17, was assigned to CARBIOGENE THERAPEUTICS Co. LTD (Hangzhou, China).

"Chimeric antigen receptor t lymphocyte for treating tumors, preparation method therefor, and use thereof" was invented by Jiangao Zhu (Hangzhou, China) and Wenjun Yang (Hangzhou, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are a chimeric antigen receptor T lymphocyte for treating tumors, a preparation method therefor, and the use thereof. The chimeric antigen receptor successively comprises a single-chain antibody against a tumor cell surface antigen, a human hinge transmembrane region, a human intracellular signal domain, a self-cleaving pe...